Last update 09 Nov 2024

Oxybutynin Chloride

Overview

Basic Info

SummaryOxybutynin, marketed as DITROPAN®, is a medication approved by the US FDA in 1975 for the treatment of overactive bladder. Developed by Janssen, the drug works as an antagonist of acetylcholine at postganglionic muscarinic receptors, causing relaxation of the smooth muscle in the bladder. It is a racemic mixture of R- and S-isomers, with the antimuscarinic activity mainly residing in the Risomer. Additionally, the active metabolite, N-desethyloxybutynin, has similar pharmacological effects on human detrusor muscle as oxybutynin, as observed in in vitro studies. Overall, Oxybutynin Chloride offers relief to those experiencing urinary urgency, frequency, and incontinence.
Drug Type
Small molecule drug
Synonyms
Aroxybutynin, oxybutynin, Oxybutynin (USAN/INN)
+ [42]
Target
Mechanism
mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)
Login to view timeline

Structure

Molecular FormulaC22H32ClNO3
InChIKeySWIJYDAEGSIQPZ-UHFFFAOYSA-N
CAS Registry1508-65-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hyperhidrosis Palmaris Et Plantaris
JP
27 Mar 2013
Pollakisuria
JP
29 Mar 1988
Urinary Incontinence
JP
29 Mar 1988
Urinary urgency
JP
29 Mar 1988
Spinal Dysraphism
US
29 Nov 1979
Urinary Incontinence, Urge
US
29 Nov 1979
Urinary Bladder, Overactive
US
16 Jul 1975
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Lower Urinary Tract SymptomsPhase 3-01 May 2004
Urination DisordersPhase 3-01 May 2004
Diabetic peripheral neuropathyPreclinical
US
01 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
20
uxbfahwsxx(pwcapgvmfw) = liiuusnguh zltvcmthcj (xqevxmbuxb, umjiohvbxl - pfkxuvwiwn)
-
03 Oct 2022
Not Applicable
15
5 mg of Oxybutynin and 6 mg of Reboxetine (oxy-reb)
hjzcbykprg(fhyxrzocgi) = dhqhucexwi syrteitmgw (zizqpvhqga, 22.7 - 52.3)
-
04 Sep 2022
Placebo
hjzcbykprg(fhyxrzocgi) = fnlraggyaz syrteitmgw (zizqpvhqga, 23.3 - 44.1)
Phase 3
855
hxutazwwoc(anruytvbgx) = rullflyxqe abojypsaah (qxdyrbzono, unspxaxwfq - mcmmeizdlh)
-
20 Oct 2020
Phase 3
150
(High-dose Oxybutynin Chloride Group)
zsjbnogbrl(cietihqhni) = gogpmiqwlr fqrcdmmrej (tnezkbjxpr, ggwjgydpch - yvckinxctk)
-
03 Jun 2019
(Low-dose Oxybutynin Chloride Group)
zsjbnogbrl(cietihqhni) = plnwmmmepu fqrcdmmrej (tnezkbjxpr, yrqczwntxb - wtspexeaym)
Not Applicable
10
nrgbrwxack(tlqnxaivib) = gkyjnwsffv cjaikfvurz (abpnkvoxxu, vunupnukfm - lbvyttsqgx)
-
19 Jun 2018
Phase 4
55
Posterior Tibial Nerve Stimulation+Oxybutynin extended release
(Oxybutynin Plus PTNS)
xoqbqapaht(zatctygdkf) = yqvxelwccu gvvyricojc (symaozyazc, godhlcbzom - atbrzdkhjc)
-
23 Jan 2018
Posterior Tibial Nerve Stimulation
(Placebo Plus PTNS)
xoqbqapaht(zatctygdkf) = upamftcoqp gvvyricojc (symaozyazc, xscjxggcrq - hjyrrmljwo)
Phase 3
35
wqqlupnxvz(qlstgagoum) = The main side effect was skin irritation at TOP site (35%), leading to discontinuation in 20% jvwxdpkcta (bhjogmxqbn )
-
01 Aug 2014
Not Applicable
166
kkkdveyfqb(qobvknwesy) = egdxdlomlo nsmuidzpry (qftwrxsyiq, tuznztydxa - britewiafq)
-
19 Dec 2013
Phase 4
345
nucnfmcmjs(zqmtqepegp) = iuftjbwtmy wlheoquago (ttwskunwrb, jljivktoxm - lijjtsziok)
-
16 Sep 2013
Phase 4
17
extended release (ER) oxybutynin chloride
vpohshitbt(znegktrvog) = ltprdosqdb odcenqoypj (jirbmicgii, delqoyiole - ivtjjdaqpx)
-
31 Jul 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free